Eli Lilly’s (LLY) Loxo and Foghorm (FHTX) Collaborate for Novel Oncology Targets using Foghorn’s Gene Traffic Control Platform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. PLTR
6. JNJ
7. QQQ
8. LDOS
9. HUM
10. KTOS

Go back to Eli Lilly’s (LLY) Loxo and Foghorm (FHTX) Collaborate for Novel Oncology Targets using Foghorn’s Gene Traffic Control Platform

Eli Lilly's (LLY) Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022

December 14, 2021 5:01 PM EST

Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints at one year in LUCENT-2, a Phase 3 maintenance study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderately-to-severely... More

Foghorn’s (FHTX) Lilly/Loxo Deal is All-Around Positive, Validates Robust Drug Discovery Engine - Analyst

December 13, 2021 9:59 AM EST

Earlier today, Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control® platform. The collaboration includes a co-development... More

Foghorn Therapeutics Inc. (FHTX) Climbs 37% Following Pact with Eli Lilly & Co. (LLY)

December 13, 2021 6:15 AM EST

Foghorn Therapeutics Inc. (NASDAQ: FHTX) Climbs 37% Following Pact with Eli Lilly & Co. (NYSE: LLY)

... More